Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Candaderm is a topical combination cream containing the broad-spectrum imidazole antifungal clotrimazole (1% w/w) and the mild corticosteroid hydrocortisone (1% w/w). It is developed and marketed by AFT Pharmaceuticals for the short-term treatment of inflamed, itching, and sensitive fungal skin infections, such as tinea (athlete's foot, jock itch, ringworm), fungal skin rash, cutaneous candidiasis (thrush), and fungally infected eczema or dermatitis. Clotrimazole acts by inhibiting fungal ergosterol synthesis, leading to structural and functional impairment of the fungal cytoplasmic membrane. Hydrocortisone provides anti-inflammatory, antipruritic, and vasoconstrictive effects to relieve associated redness, swelling, and itching.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clotrimazole + hydrocortisone.